Waverley Pharma Inc V.WAVE

Healthcare Biotechnology

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.

TSXV:WAVE - Post by User

Waverley Pharma Inc > I expect news Monday with the FDA approval ,

<< Previous

Bullboard Posts

Next >>

Comment by MidtownGuyon Jul 30, 2020 1:23pm

71 Views

Post# 31344914

RE:I expect news Monday with the FDA approval ,

FDA approval? For what? Have they applied for something? I see no news from them indicating they have applied for anything. Based on what information do you say this?